A purported stockholder filed a complaint against GreenwichPharmaceuticals Inc. alleging that one of the company'sexecutive officers and an employee misrepresented the statusof the company's first product, Therafectin, the company said.The FDA last month told the Fort Washington, Pa., company(NASDAQ:GRPI) that Phase III data of the rheumatoid arthritistreatment must undergo further analysis.

(c) 1997 American Health Consultants. All rights reserved.